Radionetics Oncology reposted this
Radionetics Oncology enters into strategic agreement with Lilly. Learn more about us at www.radionetics.com
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.
External link for Radionetics Oncology
San Diego, CA 92121, US
Radionetics Oncology reposted this
Radionetics Oncology enters into strategic agreement with Lilly. Learn more about us at www.radionetics.com
Radionetics Oncology enters into strategic agreement with Lilly. Learn more about us at www.radionetics.com
Paul Grayson is speaking tomorrow at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit. Visit https://radionetics.com/ to learn more about us!
Paul Grayson presents at Guggenheim Partners Healthcare Talks Radiopharmaceuticals Day on May 13, 2024 Learn more about us at www.radionetics.com
Radionetics Oncology represented by Paul Grayson and Brett Ewald participate in Fireside Chat hosted by Truist Securities
Paul Grayson, CEO of Radionetics Oncology, participates in Jefferies 2024 Radiopharma Innovation Summit. Learn more about us at www.radionetics.com
Radionetics Oncology announces participation in Goldman Sachs Healthruption: Third Anual Healthcare Disruption Conference
Connect with Paul Grayson or Brett Ewald for an in-person meeting at #jpm2024 www.radionetics.com
Welcome Paul Grayson! We are thrilled to have you in the team! www.radionetics.com
We continue to push forward an exciting pipeline of first-in-class targets for #radiopharmaceuticals with the support of our partners Frazier Life Sciences, 5AM Ventures,Crinetics Pharmaceuticals, DCVC Bio, GordonMD® Global Investments LP www.radionetics.com